Get the Stockscreener App
62.58
4.39%
2.63
After Hours:
62.58
Keros Therapeutics Inc stock is traded at $62.58, with a volume of 321.45K.
It is up +4.39% in the last 24 hours and up +2.76% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$59.95
Open:
$60
24h Volume:
321.45K
Relative Volume:
1.00
Market Cap:
$2.35B
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-13.78
EPS:
-4.54
Net Cash Flow:
$-146.15M
1W Performance:
+4.06%
1M Performance:
+2.76%
6M Performance:
+3.32%
1Y Performance:
+95.93%
1-Day Range:
$59.47
$62.93
1-Week Range:
$57.53
$62.93
52-Week Range:
$27.31
$73.00
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-24 | Initiated | William Blair | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
Keros Therapeutics (NASDAQ:KROS) Now Covered by Jefferies Financial Group - MarketBeat
(KROS) Proactive Strategies - Stock Traders Daily
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition - GlobeNewswire
Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Emerald Advisers LLC Acquires Shares of 155,545 Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $89.11 - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat
Analysts Offer Predictions for KROS FY2024 Earnings - Defense World
Assenagon Asset Management S.A. Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Cantor Fitzgerald Weighs in on KROS FY2024 Earnings - Defense World
Brokers Set Expectations for KROS FY2024 Earnings - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Now Covered by Cantor Fitzgerald - Defense World
(KROS) Trading Signals - Stock Traders Daily
Cantor Fitzgerald initiates coverage on Keros Therapeutics shares with Overweight rating - Investing.com India
Cantor Fitzgerald initiates coverage on Keros Therapeutics shares with Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald Initiates Coverage on Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Now Covered by Scotiabank - MarketBeat
Keros Therapeutics appoints new Chief Medical Officer - Investing.com
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer - GlobeNewswire
Keros Therapeutics appoints new Chief Medical Officer By Investing.com - Investing.com UK
Keros Therapeutics, Inc. Appoints Yung H. Chyung as Chief Medical Officer, Effective as of November 1, 2024 - Marketscreener.com
Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Declines By 13.7% - MarketBeat
Objective long/short (KROS) Report - Stock Traders Daily
Renaissance Technologies LLC Invests $654,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Renaissance Technologies LLC Acquires New Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Marshall Wace LLP Has $1.02 Million Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Dimensional Fund Advisors LP Sells 3,691 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
19,832 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Squarepoint Ops LLC - Defense World
Squarepoint Ops LLC Buys New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Point72 Asia Singapore Pte. Ltd. Buys New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $90.63 Consensus PT from Analysts - MarketBeat
Understanding the Risks of Investing in Keros Therapeutics Inc (KROS) - Knox Daily
Keros Therapeutics completes enrollment for TROPOS trial - Investing.com India
Leerink Partners sees favorable conditions for Keros Therapeutics shares amid competitive landscape with Winrevair - Investing.com Canada
Nantahala Capital Management LLC Grows Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Nantahala Capital Management LLC Acquires 84,810 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Point72 Asset Management L.P. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics completes enrollment for TROPOS trial By Investing.com - Investing.com South Africa
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Wells Fargo Initiates Coverage of Keros Therapeutics (KROS) with Overweight Recommendation - MSN
Point72 Asia Singapore Pte. Ltd. Purchases New Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Blue Owl Capital Holdings LP Sells 15,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Fred Alger Management LLC Has $2.24 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Iron Deficiency Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Shield Therapeutics, Zeria Pharma, Keros Therapeutics - The Globe and Mail
Darwin Global Management Ltd. Boosts Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Myelofibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo - The Globe and Mail
17,540 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Purchased by Point72 DIFC Ltd - MarketBeat
Keros Therapeutics Inc [KROS] Insider GORDON CARL L sells 250,000 Shares for $250,000 - Knox Daily
Keros Therapeutics Inc (KROS)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $55.80 - Defense World
Keros Therapeutics (NASDAQ:KROS) Receives New Coverage from Analysts at Guggenheim - Defense World
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Keros Therapeutics Inc Stock (KROS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):